[What are the risks of not intensively treating a chronic inflammatory disease?].
With more than 10 years of experience in rheumatology and thousands of patients treated, the infectious and oncological risks of TNF-alpha blocking agents are well known. The efficacy of biotherapies in rheumatismal diseases has been largely demonstrated. The recent review of publications and communications shows that biotherapies benefit the comorbidities associated with inflammatory rheumatisms (uveitis, Crohn disease, hemorrhagic rectocolitis, stroke, myocardial infarction). They can even reduce the excess mortality of chronic rheumatoid inflammatory diseases.
Goupille
P
P
Service de Rhumatologie, CHRU de Tours, Hôpital Trousseau, 37044 Tours, France. goupille@med.univ-tours.fr
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000209:etiology / Q000628:therapy; D002908:Chronic Disease; D003879:Dermatologic Agents / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000150:complications* / Q000628:therapy*; D000069285:Infliximab; D011565:Psoriasis / Q000150:complications / Q000628:therapy*; D012307:Risk Factors; D025241:Spondylarthritis / Q000188:drug therapy / Q000209:etiology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000209:etiology
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab